Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 13/20 | 0.60 |
| ▸ | PPARA | Q07869 | 13/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | VDR | P11473 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034707 | 0.93 | KDR (0.63) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL4033723 | 0.92 | KDR (0.62) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL4030232 | 0.92 | KDR (0.62) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL4029981 | 0.91 | KDR (0.61) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL4036830 | 0.91 | KDR (0.61) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL4397128 | 0.91 | PPARG (0.68) | KDRPPARGPPARA | |
| SCHEMBL14514345 | 0.90 | KDR (0.78) | KDRPPARGPPARAFFAR1CYP2C9 | |
| SCHEMBL4029143 | 0.90 | KDR (0.60) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL12617671 | 0.90 | KDR (0.70) | KDRPPARGPPARAFFAR1MAPT | |
| SCHEMBL4397172 | 0.89 | PPARG (0.64) | KDRPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652061-B2 | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1067109-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1638963-B1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-7211591-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211591-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211591-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060135593-A1 | N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors | NOVARTIS AG (CH) | 2006-06-22 | — | — | US | disclosed |
| US-7037914-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1638963-A1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | Novartis AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004103995-A1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
| US-6506757-B1 | A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative, is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135593-A1 | N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors | PPARG, PPARA, PPARD | KDR 838/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.